Prescription medicine
Perampanel Brand names: Fycompa
Perampanel (Fycompa) is a prescription medicine with an FDA approval on record since 2012. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $14.43 per perampanel 4 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
- DEA Schedule III
Check it at the source: the perampanel FDA label on DailyMed (effective September 1, 2024, Teva Pharmaceuticals, Inc.); the NDA 202834 record on Drugs@FDA; every perampanel label on DailyMed.
Highlights of the record
FDA label of September 1, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS.
Serious or life-threatening psychiatric and behavioral adverse reactions including aggression, hostility, irritability, anger, and homicidal ideation and threats have been reported in patients taking perampanel tablets ( 5.1 ). These reactions occurred in patients with and without prior psychiatric history, prior aggressive behavior, or concomitant use of medications associated with hostility and aggression ( 5.1 ). Advise patients and caregivers to contact a healthcare provider immediately if any of these reactions or changes in mood, behavior, or personality that are not typical for the patient are observed while taking perampanel tablets or after discontinuing perampanel tablets ( 5.1 ). Closely monitor patients particularly during the titration period and at higher doses ( 5.1 ). Perampanel tablets should be reduced if these symptoms occur and should be discontinued immediately if symptoms are severe or are worsening ( 5.1 ). WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS See full prescribing information for complete boxed warning. […]
Used for
From the label: indications and usagePerampanel tablets, a non-competitive AMPA glutamate receptor antagonist, are indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures Perampanel tabl
Forms and strengths
- 2 mg
- 4 mg
- 6 mg
- 8 mg
- 10 mg
- 12 mg
- 0.5 mg/ml
Film-coated tablet; tablet; suspension.
On the market
- Earliest approval on file
- October 22, 2012 Fycompa, Catalyst Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 5 first May 23, 2025; 5 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 3 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- July 1, 2026 Fycompa tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $14.43 per tablet Perampanel 4 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2026 0 Class I among all firms' recalls; latest June 17, 2026
- FAERS reports
- 7,532 through July 30, 2026
What is perampanel used for?
From the label: indications and usagePerampanel tablets, a non-competitive AMPA glutamate receptor antagonist, are indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) 1.1 Partial-Onset Seizures Perampanel tablets are indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older. 1.2 Primary Generalized Tonic-Clonic Seizures Perampanel tablets are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. […]
Conditions named in the indications of perampanel's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Noncompetitive AMPA Glutamate Receptor Antagonist.
Source: FDA drug label (Perampanel), Teva Pharmaceuticals, Inc., effective September 1, 2024 (SPL set bc8f7cf2-c19c-4235-859f-9ff1dd21908e), via openFDA; the full label on DailyMed
What does the patient leaflet for perampanel say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about perampanel tablets?Perampanel tablets may cause mental (psychiatric) problems, including: new or worse aggressive behavior (including homicidal behavior), hostility, anger, anxiety, or irritability being suspicious or distrustful (believing things that are not true) seeing objects or hearing things that are not there confusion difficulty with memory other unusual or extreme changes in behavior or mood Tell your healthcare provider right away if you have any new or worsening mental problems while taking perampanel tablets. 2. Like other antiepileptic drugs, perampanel tablets may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying new or worse depression feeling agitated or restless trouble sleeping (insomnia) acting aggressive, being angry, or violent an extreme increase in activity and talking (mania) attempt to commit suicide new or worse anxiety panic attacks new or worse irritability acting on dangerous impulses other unusual changes in behavior or mood Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop perampanel tablets without first talking with a healthcare provider. Stopping perampanel tablets suddenly can cause serious problems. […]
From the patient leaflet: What should I avoid while taking perampanel tablets?Do not drive, operate heavy machinery, or do other dangerous activities until you know how perampanel tablets affect you. Perampanel tablets may make you dizzy, sleepy, or tired. Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking perampanel tablets until you talk to your healthcare provider. Perampanel tablets taken with alcohol or medicines that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Perampanel tablets when taken with alcohol may also make your mood worse, increase anger, confusion, and depression.
From the patient leaflet: How should I store perampanel tablets?Store perampanel tablets at room temperature between 68° to 77°F (20° to 25°C). Keep perampanel tablets and all medicines out of the reach of children.
Source: FDA drug label (Perampanel), Teva Pharmaceuticals, Inc., effective September 1, 2024 (SPL set bc8f7cf2-c19c-4235-859f-9ff1dd21908e), via openFDA; the full label on DailyMed
Is there a generic for perampanel (Fycompa)?
The FDA approved the first generic perampanel on May 23, 2025. 5 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists perampanel from 3 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Fycompa tablets: the compound patent runs to July 1, 2026. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2012 earliest approval on file
- 2025 first generic approved
- 2026 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for perampanel (Fycompa)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $14.43 per Perampanel 4 mg tablet, down 54% from $31.28 on October 8, 2025. The survey records the price, not the reason for a change; large moves often follow a new generic or a list-price change. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Perampanel 2 mg tablet (generic)
- Fycompa 0.5 mg/mL oral suspension (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Perampanel 0.5 mg/mL oral suspension | Generic | $3.95 per mL | n/a | n/a |
| Perampanel 10 mg tablet | Generic | $15.64 per tablet | $469.30 | n/a |
| Perampanel 12 mg tablet | Generic | $14.40 per tablet | $431.92 | -54% |
| Perampanel 2 mg tablet | Generic | $6.43 per tablet | $192.95 | -58% |
| Perampanel 4 mg tablet | Generic | $14.43 per tablet | $433.02 | -54% |
| Perampanel 6 mg tablet | Generic | $18.30 per tablet | $549.14 | -45% |
| Perampanel 8 mg tablet | Generic | $18.38 per tablet | $551.29 | n/a |
| Fycompa 0.5 mg/mL oral suspension | Brand | $4.46 per mL | n/a | -0.2% |
| Fycompa 10 mg tablet | Brand | $39.12 per tablet | $1,173.46 | -0.1% |
| Fycompa 12 mg tablet | Brand | $39.11 per tablet | $1,173.29 | -0.3% |
| Fycompa 2 mg tablet | Brand | $19.75 per tablet | $592.63 | -0.3% |
| Fycompa 4 mg tablet | Brand | $39.14 per tablet | $1,174.21 | -0.1% |
| Fycompa 6 mg tablet | Brand | $39.13 per tablet | $1,174.00 | -0.1% |
| Fycompa 8 mg tablet | Brand | $39.09 per tablet | $1,172.62 | -0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has perampanel been recalled?
The FDA's Enforcement Report lists 1 recall naming perampanel since 2026: 0 Class I (the most serious), 1 Class II, 0 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| June 17, 2026 | Class II | SUN PHARMACEUTICAL INDUSTRIES INC | Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the perampanel label say about other medicines?
The perampanel label names 4 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Carbamazepine | drug interactions | DRUG INTERACTIONS Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. |
| Levonorgestrel | drug interactions | DRUG INTERACTIONS Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. |
| Oxcarbazepine | drug interactions | DRUG INTERACTIONS Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. |
| Phenytoin | drug interactions | DRUG INTERACTIONS Contraceptives: 12 mg once daily may decrease the effectiveness of hormonal contraceptives containing levonorgestrel ( 7.1 ) Moderate and Strong CYP3A4 Inducers (including carbamazepine, oxcarbazepine, and phenytoin): increase clearance of perampanel and decrease perampanel plasma concentrations. |
Source: FDA drug label (Perampanel), Teva Pharmaceuticals, Inc., effective September 1, 2024 (SPL set bc8f7cf2-c19c-4235-859f-9ff1dd21908e), via openFDA; the full label on DailyMed
What do FAERS reports show for perampanel?
The FDA Adverse Event Reporting System holds 7,532 reports that list perampanel among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 466 are coded as a death and 2,899 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as perampanel?
18 other medicines are given the same way (oral) and in the same FDA class as perampanel or labeled mainly for the same use (seizures and epilepsy), the same class first. Seizures and epilepsy lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Topiramate | Seizures and epilepsy | 47 labelers | $0.0567 per tablet 100 mg tablet | No current entry |
| Lamotrigine | Seizures and epilepsy | 50 labelers | $0.0268 per tablet 25 mg tablet | A presentation being discontinued |
| Levetiracetam | Seizures and epilepsy | 63 labelers | $0.0736 per tablet 500 mg tablet | No current entry |
| Phenobarbital | Seizures and epilepsy | none listed | $0.213 per tablet 100 mg tablet | A presentation being discontinued |
| Clonazepam | Seizures and epilepsy | 31 labelers | $0.0244 per tablet 1 mg tablet | In shortage |
| Lacosamide | Seizures and epilepsy | 43 labelers | $0.174 per tablet 100 mg tablet | No current entry |
| Oxcarbazepine | Seizures and epilepsy | 43 labelers | $0.167 per tablet 300 mg tablet | No current entry |
| Brivaracetam | Seizures and epilepsy | 14 labelers | $0.259 per tablet 100 mg tablet | No current entry |
Every medicine labeled for the same conditions as perampanel
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to perampanel
- 18 medicines for the same use
- Perampanel side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other